Abstract: The present invention describes methods and uses of antibodies targeting the C?1 or the C?2 chain of a TCR, in particular an anti-C?1 antibody, for enrichment of T cells expressing a desired antigen-specific recombinant T cell receptor (TCR).

Abstract: The invention relates to a method for generating an antibody binding to a cell surface protein of interest, the method comprising the following steps: (a) providing a non-human cell which does not express the endogenous form of the cell surface protein of interest but expresses an exogenous form of the cell surface protein of interest comprising at least one human segment; (b) immunization of a non-human animal with the cell line provided in step (a); (c) generation of hybridomas from the immunized non-human animal of step (b); (d) screening for an antibody that binds to the cell surface protein of interest by contacting the antibodies secreted by the hybridomas of step (c) with human cells which do not express the endogenous form of the cell surface protein of interest but express an exogenous form of the cell surface protein of interest comprising at least one human segment.

Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.

Abstract: The present invention relates to (nucleic acids encoding) inducible T cell receptors (iTCRs), compositions and kits, vectors and host cells comprising such (nucleic acids encoding) inducible T cell receptors, uses thereof in preparing inducible T cell receptors and host cells comprising such T cell receptors, methods for preparing such inducible T cell receptors and for dimerizing T cell receptors, as well as medical uses of such compounds and pharmaceutical compositions comprising them, particularly for treating cancer. The present invention relates to combinations comprising one or more nucleic acid molecules, said one or more nucleic acid molecules comprising a nucleic acid sequence A encoding for a TCR alpha chain linked to a dimerization domain, and a nucleic acid sequence B encoding for a TCR beta chain linked to a dimerization domain, as well as proteins encoded by such nucleic acid molecules and corresponding uses and methods.

Abstract: The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.

Abstract: The invention relates to a library for the expression of all functional TCR types comprising 45 TCR constructs each encoding one of the 45 different TCR ? chains and 47 TCR constructs each encoding one of the 47 different TCR ? chains, wherein each of the 45 TCR constructs encoding one of 45 different TCR ? chain comprises the following building blocks one of the variable AV segments AVseg1 to AVseg45, and a constant AC segment, and wherein each of the 47 TCR constructs encoding one of 47 different TCR ? chains comprises one of the variable BV segments BVseg1 to BVseg47, and a constant BC segment.

Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.

Abstract: The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.

Abstract: The present invention relates to an antibody or binding fragment thereof that binds to a fraction of T cell receptor variable alpha (TCR V?) chains comprising at least two different TCR V? chains but less than all TCR V? chains or that binds to a fraction of T cell receptor variable beta (TCR V?) chains comprising at least two different TCR V? chains but less than all TCR V? chains.

Abstract: The invention relates to a library for the expression of all functional TCR types comprising 45 TCR constructs each encoding one of the 45 different TCR ? chains and 47 TCR constructs each encoding one of the 47 different TCR ? chains, wherein each of the 45 TCR constructs encoding one of 45 different TCR ? chain comprises the following building blocks one of the variable AV segments AVseg1 to AVseg45, and a constant AC segment, and wherein each of the 47 TCR constructs encoding one of 47 different TCR ? chains comprises one of the variable BV segments BVseg1 to BVseg47, and a constant BC segment.

Abstract: The invention relates to a method for generating an antibody binding to a cell surface protein of interest, the method comprising the following steps: (a) providing a non-human cell which does not express the endogenous form of the cell surface protein of interest but expresses an exogenous form of the cell surface protein of interest comprising at least one human segment; (b) immunization of a non-human animal with the cell line provided in step (a); (c) generation of hybridomas from the immunized non-human animal of step (b); (d) screening for an antibody that binds to the cell surface protein of interest by contacting the antibodies secreted by the hybridomas of step (c) with human cells which do not express the endogenous form of the cell surface protein of interest but express an exogenous form of the cell surface protein of interest comprising at least one human segment.

Abstract: The present invention is directed to a method of identifying CD4+ T cell antigens as well as to antigens which were identified by such a method. The present invention further is directed to the application of those identified antigens in medicine.

Abstract: The present invention is directed to a method of identifying CD4+ T cell antigens as well as to antigens which were identified by such a method. The present invention further is directed to the application of those identified antigens in medicine.